{"id":52703,"date":"2023-01-09T17:02:18","date_gmt":"2023-01-09T16:02:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/"},"modified":"2023-01-09T17:02:18","modified_gmt":"2023-01-09T16:02:18","slug":"boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/","title":{"rendered":"Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies"},"content":{"rendered":"
\n

INGELHEIM, Germany & SAN FRANCISCO–(BUSINESS WIRE)–Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences\u2019 best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim\u2019s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds, further strengthening the company\u2019s pipeline.\n<\/p>\n

<\/a><\/p>\n

\nCancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T\u2018s platform aims to address this challenge by identifying novel shared T-cell receptor (TCR) targets of productive immune responses and comprehensively screening TCRs and TCR mimetics for specificity and off-target cross-reactivities. The platform identifies the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning. This may lead to tumor-specific, safer therapies that can be delivered at higher doses.\n<\/p>\n

\n\u201cAt Boehringer Ingelheim, we are committed to transforming patients\u2019 lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,\u201d said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.\n<\/p>\n

\n\u201cOn behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,\u201d said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. \u201c3T\u2019s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.\u201d\n<\/p>\n

\nUnder the agreement, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T\u2019s target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones totaling $268 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.\n<\/p>\n

\nFor the full press release and link to \u201cNotes to Editors\u201d please click here:
\n
Press Release<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia contacts:<\/b>\n<\/p>\n

\nB<\/b>oehringer Ingelheim<\/b>
Dr. Reinhard Malin<\/b>
Boehringer Ingelheim Corporate Center GmbH
\n
Innovation Unit\/Bio Comms, Corp. Affairs
\n
Media + PR
\n
press@boehringer-ingelheim.com<\/a>\n<\/p>\n

\nLinda Ruckel<\/b>
Boehringer Ingelheim Corporate Center GmbH
\n
Innovation Unit\/Bio Comms, Corp. Affairs
\n
Media + PR
\n
P: 203-791-6672
\n
press@boehringer-ingelheim.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

INGELHEIM, Germany & SAN FRANCISCO–(BUSINESS WIRE)–Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences\u2019 best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim\u2019s … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52703","6":"format-standard","7":"category-industry"},"yoast_head":"\nBoehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"INGELHEIM, Germany & SAN FRANCISCO–(BUSINESS WIRE)–Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences\u2019 best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim\u2019s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-09T16:02:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230109005420\/en\/732799\/21\/BI_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies\",\"datePublished\":\"2023-01-09T16:02:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\\\/\"},\"wordCount\":434,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005420\\\/en\\\/732799\\\/21\\\/BI_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\\\/\",\"name\":\"Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005420\\\/en\\\/732799\\\/21\\\/BI_Logo.jpg\",\"datePublished\":\"2023-01-09T16:02:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005420\\\/en\\\/732799\\\/21\\\/BI_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005420\\\/en\\\/732799\\\/21\\\/BI_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies - Pharma Trend","og_description":"INGELHEIM, Germany & SAN FRANCISCO–(BUSINESS WIRE)–Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences\u2019 best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim\u2019s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-09T16:02:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230109005420\/en\/732799\/21\/BI_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies","datePublished":"2023-01-09T16:02:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/"},"wordCount":434,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230109005420\/en\/732799\/21\/BI_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/","url":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/","name":"Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230109005420\/en\/732799\/21\/BI_Logo.jpg","datePublished":"2023-01-09T16:02:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230109005420\/en\/732799\/21\/BI_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230109005420\/en\/732799\/21\/BI_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52703"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52703\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}